Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
about
Laparoscopic gastric cancer surgery: Current evidence and future perspectivesColon cancer screening with image-enhanced endoscopyIncidence of kidney, bladder, and prostate cancers in Korea: An updateClinical manifestation of cancer related stroke: retrospective case-control study.Attributable fraction of alcohol consumption on cancer using population-based nationwide cancer incidence and mortality data in the Republic of KoreaComputational Discrimination of Breast Cancer for Korean Women Based on Epidemiologic Data OnlyMultiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study.Low C24-OH and C22-OH sulfatides in human renal cell carcinoma.Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer.Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status.Retrospective analysis of treatment outcomes after postoperative chemoradiotherapy in advanced gastric cancerIrinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer.Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin TreatmentPreclinical efficacy testing for stomach and liver cancers.Comprehension of readmission after laparoscopy assisted distal gastrectomy: what are the causes?Value of Surveillance (18)F-FDG PET/CT in Colorectal Cancer: Comparison with Conventional Imaging Studies.Alternative medical treatment for radioiodine-refractory thyroid cancers.Colorectal cancer mortality in Inner Mongolia between 2008 and 2012.Combined effects of smoking and bilirubin levels on the risk of lung cancer in Korea: the severance cohort studyInfluenza vaccination and associated factors among Korean cancer survivors : a cross-sectional analysis of the Fourth & Fifth Korea National Health and Nutrition Examination Surveys.Connexin32 inhibits gastric carcinogenesis through cell cycle arrest and altered expression of p21Cip1 and p27Kip1Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival.Population-based survival data for brain tumors in Korea.Body mass index as a predictor of advanced colorectal neoplasia.Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer.Association of ATM Gene Polymorphism with PTC Metastasis in Female Patients.The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancerRisk factors for distant metastasis as a primary site of treatment failure in early-stage breast cancer.Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapyColorectal cancers from distinct ancestral populations show variations in BRAF mutation frequencyValidity of fecal occult blood test in the national cancer screening program, Korea.Risk factors and control strategies for the rapidly rising rate of breast cancer in Korea.Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2010.Incidence of primary spinal cord, spinal meninges, and cauda equina tumors in Korea, 2006-2010.Gastric cancer epidemiology in Korea.Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis.A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis.Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancerEffectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer.
P2860
Q26774648-9A1B627C-5431-4B75-B8B0-56E91560160FQ27028087-C61CD902-B835-4F15-AC84-BBF0721BD87CQ28082161-34C5D8D3-E6AE-42D2-A358-AD2DB341683BQ30585137-9931919E-B8D2-484C-9ABC-667EDFFB6565Q30830331-76234E18-0D03-4F91-88CD-966250981632Q30984936-ADD2A734-8ED6-46E8-8988-4407542D1B58Q31102359-56101746-4A69-44FB-9777-497937F6060CQ31160691-AA8B474B-BFA6-4108-B1AC-EBB42C540927Q33396630-906A9AC6-72D8-45A0-A728-AC43A4B4C784Q33402018-52CE88DE-6992-4BF8-A517-CAAD3E729E5DQ33403352-D3B22F6B-EC56-4390-B9D6-F8DEE3845AB3Q33404645-1DFE551C-0EF2-4CEC-8E3E-0FCFCEB68E35Q33619249-03837C17-0EC3-493D-8F9B-1B7BCF40ABF6Q33619259-29A09410-A28B-4F07-92FE-188608020C55Q33627452-24799178-ED79-4061-B248-EE2DD9EA699FQ33704530-1CE13D48-0F2C-4ED4-AE3A-18EB96753B6EQ33704599-EB39ED6A-4050-4035-852F-38D028F4C83BQ33845558-DD20510B-2359-4553-A321-38FD5468411DQ34011326-9E85A9CF-1963-480E-B857-0F5FD2F8AB83Q34029923-707A092C-9EF2-4509-96C6-7DE95B209086Q34049242-2E21F35D-54C7-47A1-8D0E-19588763ECF3Q34284145-85CD2104-BB73-4208-A86A-4ECACB8DF072Q34290509-4ADC860C-384E-4719-9F6A-5546CB650DF8Q34305345-C24677C3-A05F-4210-AE66-EBAA13C94C7DQ34372824-5F60ADBE-52CA-4DCD-A93D-AED03AF38A0EQ34438260-F66DA9A8-2F34-4099-84D8-F371D34A5FDFQ34572068-858B76CA-3A64-48E4-A818-B1C1DD4547F8Q34760981-5E1A2744-9DCD-47F4-BBEA-B08139285184Q34774308-A4C924C7-35B1-4517-B6CD-04FF4E47F90FQ34857119-CE0291A9-ADB3-49BD-B0B8-E56817F9253FQ34997425-0669E4B4-D633-4F00-B525-A7D0C1CB8097Q35048312-6E0BE0A4-C882-4DD6-B6EC-CDC503EC149BQ35142220-2C0F046A-7899-4C39-911E-557F02C33904Q35340858-38EF6C9C-E04B-4A3F-9185-D7EFDA47FFCCQ35429959-8D02E0FF-EED9-4294-90AB-642DF94BD484Q35480890-A13B451A-22E9-47D2-9CBA-2A4F7D65EE5EQ35661049-8241A739-701A-4552-A079-4F606F8306D2Q35661054-5E26D0B8-6616-4707-A20D-A563BDA63FFAQ35661060-5111AC7A-3069-4997-B219-9D22F5C438E9Q35675831-33872D36-5CCD-4B63-87D4-EEF621E922DA
P2860
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@ast
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@en
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@nl
type
label
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@ast
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@en
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@nl
prefLabel
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@ast
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@en
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@nl
P2093
P2860
P356
P1476
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008
@en
P2093
Hyun-Joo Kong
Jin-Soo Lee
Joo Young Lee
Kyu-Won Jung
Sohee Park
Young-Joo Won
P2860
P356
10.4143/CRT.2011.43.1.1
P577
2011-03-31T00:00:00Z